Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease

Clinical Trial Phase I / II Prospective, Open, Non-randomized for Treatment of Lumbar Intervertebral Degenerative Disc Disease With Posterolateral Instrumented and Autologous Mesenchymal Stem Cells.

The purpose of this trial is to test the effectiveness of the use of a new therapeutic strategy in treating patients with degenerative disc disease lumbar intervertebral fusion with instrumented posterolateral autologous mesenchymal stem cells and arranged in a calcium phosphate ceramic (Conduit TM).

Inclusion Criteria:

Clinical

• Box symptomatic (back pain and / or root) of lumbar degenerative disc disease monosegmental.
• Discopathy refractory to conservative treatment (drugs, physical therapy.)
• Evolution greater than or equal to 6 months. Radiological
• Discopathy radiation. Disc space narrowing, osteophytes, abnormal mobility, etc
• NMR: grades IV and V of Pfirman.

Exclusion Criteria:

• Rejection of surgical treatment.
• Systemic inflammatory disease (spondylitis, rheumatoid arthritis etc), tumor or infection.
• Immunosuppressive treatment.
• Congenital or acquired anatomical abnormality that prevents the surgical procedure.
• Neuropsychiatric pathology, drug addiction, psychosis, severe personality disorder.
• High surgical risk (ASA> IV), or contraindication to anesthesia.